RIBOCICLIB (RIB) plus LETROZOLE (LET) IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE (HR plus ), HUMAN EPIDERMAL RECEPTOR-2-NEGATIVE (HER2-) ADVANCED BREAST CANCER (ABC) BY DOSE INTENSITY: PRELIMINARY SUBGROUP RESULTS FROM THE PHASE 3B COMPLEEMENT-1 TRIAL

被引：0
|
作者：
Farhat, Fadi [6 ]
Martin, Miguel [7 ]
Campone, Mario [8 ]
Bachelot, Thomas [1 ]
Neven, Patrick [12 ]
Martinez Rodriguez, Jorge Luis [3 ,4 ]
Yusof, Mastura Md [11 ]
Papazisis, Konstantinos [5 ]
Ferreira, Ana [2 ]
Ankrah, Nii [9 ]
Wu, Jiwen [9 ]
Zhou, Katie [9 ]
De laurentiis, Michelino [10 ]
机构：
[1] Ctr Leon Berard, Dept Med Oncol, Lyon, France
[2] CUF Porto Hosp, Inst CUF Oncol, Porto, Portugal
[3] Escuela Nacl Med, Monterrey, Nuevo Leon, Mexico
[4] Tecnol Monterrey, Monterrey, Nuevo Leon, Mexico
[5] Euromed Gen Clin, Dept Oncol, Thessaloniki, Greece
[6] Hammoud Hosp UMC, Hematol Oncol Div, Saida, Lebanon
[7] Hosp Gregorio Maranon, Dept Oncol, Madrid, Spain
[8] Inst Canc Res Western France ICO, Lyon, France
[9] Novartis Pharmaceut, E Hanover, NJ USA
[10] Natl Canc Inst, Fdn Pascale, Naples, Italy
[11] Pantai Hosp, Dept Oncol, Kuala Lumpur, Malaysia
[12] Univ Hosp Leuven UZ Leuven, Dept Obstet Gynecol, Leuven, Belgium
来源：
BREAST | 2019年 / 48卷
关键词：
D O I：
10.1016/S0960-9776(19)30676-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO67
引用
收藏
页码：S46 / S46
页数：1
相关论文
共 50 条
  • [31] First-line ribociclib plus letrozole in postmenopausal Asian women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): A subgroup analysis from MONALEESA-2
    Yap, Y. S.
    Tseng, L-M.
    Blackwell, K. L.
    Cameron, D.
    Foo, S.
    Sriuranpong, V.
    Huang, C-S.
    Chao, T-Y.
    Kim, T-Y.
    Chen, S-C.
    Jung, K. H.
    Lee, K. S.
    Sohn, J-H.
    Kim, J. H.
    Hou, M-F.
    Han, Y.
    Souami, F.
    Dhuria, S.
    Miller, M.
    Verma, S.
    ANNALS OF ONCOLOGY, 2016, 27
  • [32] First-line ribociclib plus letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-), advanced breast cancer (ABC)
    Hortobagyi, G. N.
    Stemmer, S. M.
    Burris, H. A.
    Yap, Y. S.
    Sonke, G. S.
    Paluch-Shimon, S.
    Campone, M.
    Blackwell, K.
    Andre, F.
    Winer, E. P.
    Janni, W.
    Verma, S.
    Conte, P.
    Arteaga, C. L.
    Cameron, D.
    Xuan, F.
    Souami, F.
    Miller, M.
    Germa, C.
    O'Shaughnessy, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [33] Ribociclib (RIB) plus endocrine therapy (ET) in Japanese women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC)
    Masuda, N.
    Noguchi, S.
    Ishikawa, T.
    Aruga, T.
    Kim, S. J.
    Toyama, T.
    Saeki, T.
    Saito, M.
    Yamanaka, T.
    Watanabe, J.
    Nakamura, S.
    Takahashi, M.
    Inoue, K.
    Gounaris, I.
    Han, Y.
    Samant, T. S.
    Gazdoiu, M.
    Ito, Y.
    ANNALS OF ONCOLOGY, 2018, 29
  • [34] Ribociclib plus letrozole for first-line treatment of hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): efficacy by baseline tumor markers
    Andre, Fabrice
    Stemmer, Salomon M.
    Campone, Mario
    Petrakova, Katarina
    Paluch-Shimon, Shani
    Yap, Yoon-Sim
    Marschner, Norbert
    Chan, Arlene
    Villanueva, Cristian
    Hart, Lowell L.
    Arteaga, Carlos L.
    Sonke, Gabe S.
    Grischke, Eva-Maria
    Alba, Emilio
    Nusch, Arnd
    Yardley, Denise A.
    Jakobsen, Erik
    Blau, Sibel
    Tolaney, Sara M.
    Su, Faye
    He, Wei
    Germa, Caroline
    Hortobagyi, Gabriel N.
    CANCER RESEARCH, 2017, 77
  • [35] Ribociclib (RIB) plus fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): Results from MONALEESA-3
    Slamon, Dennis J.
    Neven, Patrick
    Chia, Stephen K. L.
    Im, Seock-Ah
    Fasching, Peter A.
    DeLaurentiis, Michelino
    Petrakova, Katarina
    Bianchi, Giulia Valeria
    Esteva, Francisco J.
    Martin, Miguel
    Pivot, Xavier
    Vidam, Gena
    Wang, Yingbo
    Lorenc, Cristina Karen Rodriguez
    Miller, Michelle Kristine
    Taran, Tanya
    Jerusalem, Guy Heinrich Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [36] Phase 3b CompLEEment-1 study of ribociclib plus letrozole in the treatment of HR+/HER2-advanced breast cancer: Final results from the UK cohort
    Tuthill, Mark
    Marwaha, Hardeep
    Hartmann, Christoph E. A.
    CANCER RESEARCH, 2021, 81 (04)
  • [37] Everolimus plus exemestane for hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (BC): overall survival results from BOLERO-2
    Piccart, M.
    Hortobagyi, G. N.
    Campone, M.
    Pritchard, K. I.
    Noguchi, S.
    Rugo, H.
    Gnant, M.
    Feng, W.
    Taran, T.
    Baselga, J.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S1 - S1
  • [38] Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2-advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial
    Salvador Bofill, Javier
    Moreno Anton, Fernando
    Rodriguez Sanchez, Cesar Augusto
    Galve Calvo, Elena
    Hernando Melia, Cristina
    Ciruelos Gil, Eva Maria
    Vidal, Maria
    Jimenez-Rodriguez, Begona
    De la Cruz Merino, Luis
    Martinez Janez, Noelia
    Villanueva Vazquez, Rafael
    de Toro Salas, Ruben
    Anton Torres, Antonio
    Alvarez Lopez, Isabel Manuela
    Gavila Gregori, Joaquin
    Quiroga Garcia, Vanesa
    Vicente Rubio, Elena
    de la Haba-Rodriguez, Juan
    Gonzalez-Santiago, Santiago
    Diaz Fernandez, Nieves
    Barnadas Molins, Agusti
    Sanchez de Ibarguen, Blanca Cantos
    Delgado Mingorance, Juan Ignacio
    Bellet Ezquerra, Meritxell
    de Casa, Sonia
    Gimeno, Asuncion
    Martin, Miguel
    BREAST, 2022, 66 : 77 - 84
  • [39] Alpelisib plus letrozole in estrogen receptor-Positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (aBC): Safety and preliminary efficacy analysis from a phase 1b trial
    Juric, Dejan
    Goncalves, Anthony
    Hamilton, Erika
    Boni, Valentina
    Mayer, Ingrid A.
    Turri, Sabine
    Wang, Yingbo
    Vogl, Florian D.
    Sellami, Dalila
    Campone, Mario
    CANCER RESEARCH, 2018, 78 (04)
  • [40] Health-related quality of life (HRQoL) of postmenopausal women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with ribociclib plus letrozole: Results from MONALEESA-2.
    Verma, Sunil
    O'Shaughnessy, Joyce
    Burris, Howard A.
    Campone, Mario
    Alba, Emilio
    Chandiwana, David
    Manson, Stephanie
    Sutradhar, Santosh C.
    Monaco, Mauricio
    Janni, Wolfgang
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345